AVBP

10.5206.57%
ZY

Zhengbin Yao

Co-Founder, Chairman, President & CEO

Dr. Zhengbin Yao, also known as Bing, Ph.D., is Member of Scientific Advisory Board of Shanghai Allist Pharmaceuticals Co. Ltd. He serves as Member of Scientific Advisory Board at Bambusa Therapeutics, Inc. Dr. Yao served as Independent Non-Executive Director at VISEN Pharmaceuticals (Shanghai) Co., Ltd. since April 01, 2021 until August 27, 2026. He is the Co-Founder, Chairman, President and Chief Executive Officer of ArriVent Biopharma, Inc. and also serves as a Director since June 2021. He has been an Independent Non-executive Director at VISEN Pharmaceuticals since April 1, 2021. Dr. Yao serves as an Independent Director of Alumis Inc. (Formerly, Esker Therapeutics) since June 2021. He was an Independent Director of NexImmune, Inc. since January 2017 Until August 27, 2024. He serves as Member of Strategic Advisory Board at Sporos Bioventures since January 2022. He served as Director at Immune-Onc Therapeutics, Inc. since November 2019. Dr. Yao served as Chief Executive Officer and President of Viela Bio, Inc. since February 2018 until March 2021, which he co-founded in 2018 and served as its Chairman since January 2019 until March 15, 2021. He is Director of Viela Bio, Inc. Dr. Yao is an accomplished executive and scientist with extensive experience in the biotechnology and pharmaceutical industries. Dr. Yao has experience in the biopharmaceutical industry. From October 2010 to February 2018, Dr. Yao served in various leadership roles at MedImmune, including Senior Vice President of R&D, Head of Respiratory, Inflammation, Autoimmune iMED. Dr. Yao also served as Senior Vice President, Head of Immuno-Oncology Franchise, AstraZeneca. He served as Chief Executive Officer for WuXi-MedImmune Joint Venture. During his tenure at MedImmune and Astrazenca, he played key leadership roles in the development and approval of multiple novel biologics for autoimmune, respiratory and immuno-oncology indications. Prior to his tenure at MedImmune and AstraZeneca, Dr. Yao served as Head of PTL for Immunology, Infectious Diseases, Neuroscience and Metabolic Disease at Genentech, Inc., or Genentech. During his tenure at MedImmune and AstraZenca, he played key leadership roles in the development and approval of multiple novel biologics for autoimmune, respiratory and immune-oncology indications respectively. Previously, Dr. Yao was Vice President and Head of Research for Tanox, Inc., before it was acquired by Genentech in 2007. Before joining Aventis, Dr. Yao was a Research Scientist at Amgen in Boulder, Colo., where he was responsible for identifying and validating novel targets and managing a research laboratory. Prior to joining MedImmune, Dr. Yao led the project team leaders group for immunology, neurosciences, virology and metabolism for Genentech and prior to that, served as Vice President of research and corporate officer for Tanox before it was acquired by Genentech. He is the inventor or co-inventor on more than 20 issued patents and patent applications and has had more than 50 articles published in peer-reviewed journals. Dr. Yao also co-Chairs the MedI/AstraZenecaAmgen collaboration. Earlier in his career, Dr. Yao held key roles at Aventis and Amgen. Dr. Yao received his M.S. in Immunology at Anhui Medical University in Anhui, China. He received his Ph.D. in Microbiology and Immunology from the University of Iowa in 1994, has authored more than 50 peer-reviewed publications and holds over 20 patents and patent applications.

Positions